Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic’s Endeavor Stent Hits Primary Endpoint In Pivotal Trial

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Endeavor zotarolimus-eluting stent is as effective as Boston Scientific's Taxus paclitaxel-eluting stent in the ENDEAVOR IV trial, Medtronic announced July 2

You may also be interested in...



Medtronic Bullish About Endeavor’s Chances In U.S. Market

Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share

Zur Rose Calls For Swiss Online Liberalization To Manage Coronavirus OTC Demand

Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.

UsernamePublicRestriction

Register

MT024997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel